Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs

导出原文传递

翻译打印收藏纠错

作者： MacIag, A.E. ^[1] ; Nandurdikar, R.S. ^[2] ; Hong, S.Y. ^[3] ; Chakrapani, H. ^[4] ; Diwan, B. ^[5] ; Morris, N.L. ; Shami, P.J. ; Shiao, Y.-H. ; Anderson, L.M. ; Keefer, L.K. ; Saavedra, J.E.

作者单位： Laboratory Animal Sciences Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, MD 21702, United States ^[1] Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States ^[2] Basic Science Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, MD 21702, United States ^[3] Chemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States ^[4] Department of Chemistry, Indian Institute of Science Education and Research, Pune 411008, India ^[5]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of Medicinal Chemistry

2011年54卷22期

7751-7758页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs

Journal of Medicinal Chemistry

相似文献

Journal of Medicinal Chemistry

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs

Journal of Medicinal Chemistry

相似文献

Journal of Medicinal Chemistry

相关期刊

检索历史清除